Codiak BioSciences, Inc.
NASDAQ:CDAK
Intrinsic Value
Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CDAK.
Fundamental Analysis
Balance Sheet Decomposition
Codiak BioSciences, Inc.
| Current Assets | 61.2m |
| Cash & Short-Term Investments | 51.8m |
| Other Current Assets | 9.5m |
| Non-Current Assets | 73.2m |
| PP&E | 41.5m |
| Other Non-Current Assets | 31.7m |
| Current Liabilities | 14.5m |
| Accounts Payable | 2m |
| Accrued Liabilities | 11.1m |
| Other Current Liabilities | 1.4m |
| Non-Current Liabilities | 81m |
| Long-Term Debt | 25.7m |
| Other Non-Current Liabilities | 55.3m |
Earnings Waterfall
Codiak BioSciences, Inc.
|
Revenue
|
34.1m
USD
|
|
Operating Expenses
|
-82.9m
USD
|
|
Operating Income
|
-48.8m
USD
|
|
Other Expenses
|
31.4m
USD
|
|
Net Income
|
-17.4m
USD
|
Free Cash Flow Analysis
Codiak BioSciences, Inc.
CDAK Profitability Score
Profitability Due Diligence
Codiak BioSciences, Inc.'s profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Codiak BioSciences, Inc.'s profitability score is 25/100. The higher the profitability score, the more profitable the company is.
CDAK Solvency Score
Solvency Due Diligence
Codiak BioSciences, Inc.'s solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Codiak BioSciences, Inc.'s solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CDAK Price Targets Summary
Codiak BioSciences, Inc.
Ownership
CDAK Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CDAK Price
Codiak BioSciences, Inc.
| Average Annual Return | 36.51% |
| Standard Deviation of Annual Returns | 126.08% |
| Max Drawdown | -100% |
| Market Capitalization | 445.6k USD |
| Shares Outstanding | 36 829 600 |
| Percentage of Shares Shorted | 0.64% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2020-10-14. The firm is focused on the development of exosome-based therapeutics. The firm has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. The company utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The firm's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The firm's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).
You don't have any saved screeners yet
